news
FDA fast-tracks daridorexant for pediatric insomnia
The FDA granted breakthrough therapy designation to Idorsia's daridorexant for treating insomnia in pediatric patients. The dual orexin receptor antagonist is already approved for adults, but children and teenagers currently have zero FDA-cleared pharmacological treatments for chronic sleep disruption.
The FDA granted breakthrough therapy designation to Idorsia's daridorexant for treating insomnia in pediatric patients. The dual orexin receptor antagonist is already approved for adults, but children and teenagers currently have zero FDA-cleared pharmacological treatments for chronic sleep disruption.
The architecture take
Every pediatrician I know quietly hates the current toolkit for sleepless kids. Right now, families cycle through adult antihistamines, off-label blood pressure pills, or handfuls of melatonin gummies that flood developing hormone baselines without touching the root cause. I was skeptical when orexin blockers first hit the adult market, but the mechanism makes sense. Boring biology works.
Daridorexant targets orexin neuropeptides (the neurotransmitters that keep the brain vigilantly awake) rather than knocking out the central nervous system through GABA channels. It turns down the wake drive so natural sleep pressure can take over. I suspect the FDA moved fast because pediatricians are genuinely desperate for something that doesn't leave a twelve-year-old sedated until noon.
Watch two things happen next:
- Heavy scrutiny on daytime mood changes in late-stage trials.
- A sudden wave of off-label demand for teenagers wired on ADHD stimulants.